Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Open accessAbstract
Aims: Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label extension trials. Methods and results: Following completion of the parent trial, adult patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent, or heterozygous familial hypercholesterolaemia received open-label inclisiran twice yearly (after initial and 3-month doses) until Day 990, followed by an end-of-study visit at Day 1080 or ≥ 90 days after the last dose. The study endpoints included the proportion of patients achieving pre-specified low-density lipoprotein cholesterol (LDL-C) goals [ASCVD: < 1.8 mmol/L (< 70 mg/dL); ASCVD risk equivalent: < 2.6 mmol/L (< 100 mg/dL)], percentage and absolute changes in LDL-C at end-of-study, and safety of inclisiran. Of 3274 patients, 2446 (74.7%) were followed until end-of-study. Mean age was 64.9 ± 9.9 years, 82.7% (n = 2709) had ASCVD, and mean baseline LDL-C was 2.9 ± 1.2 mmol/L. Mean cumulative exposure to inclisiran (including parent trials) was 3.7 years; maximum exposure was 6.8 years. With inclisiran, 78.4% [95% confidence interval (CI): 76.8, 80.0] of patients achieved pre-specified LDL-C goals and mean percentage change in LDL-C was −49.4% (95% CI: −50.4, −48.3). No attenuation of LDL-C lowering over time was observed. Treatment-emergent adverse events at injection site (all mild/moderate) occurred in 5.9% of the patients. Inclisiran-associated anti-drug antibodies were infrequent (5.5%) and had no impact on the efficacy or safety of inclisiran. No new safety signals were identified. Conclusion: In the largest and longest follow-up to date with >12 000 patient-years exposure, inclisiran demonstrated consistent and effective LDL-C lowering with a favourable long-term safety and tolerability profile. Trial Registration number: ClinicalTrials.gov identifier: NCT03814187
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The mean LDL-C reduction from inclisiran 300 mg given every six months reached 49.4% in 3,274 patients who participated for an average of 3.7 years (maximum 6.8 years).
“The mean LDL-C reduction from inclisiran 300 mg given every six months reached 49.4% in 3,274 patients who participated in the study for an average of 3.7 years (maximum 6.8 years) [42].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [42]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredIn the ORION-8 long-term extension study, inclisiran achieved a 49.4% reduction of LDL-C during 3.7 years of median follow-up with no signs of tachyphylaxis.
“During the ORION-8 long-term extension study inclisiran achieved a 49.4% reduction of LDL-C during 3.7 years of median follow-up with no signs of tachyphylaxis [42].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [42]
The Results (Study outcomes; page unavailable) report a mean 49.4% LDL-C reduction at end-of-study, and the Discussion (Study limitations; page unavailable) describes sustained lowering without evidence of waning efficacy. The paper calls 3.7 years the mean cumulative treatment exposure, not the median follow-up, so that qualifier is unsupported. (LLM, conf=0.92)
Experimental — accuracy not yet measuredInclisiran proved effective for all ethnicities, BMI categories, glycemic states, and worldwide locations including South Africa, China, and Japan.
“Inclisiran proved effective for all ethnicities and BMI categories as well as glycemic states and worldwide locations including South Africa, China and Japan thus proving its worldwide application [42].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [42]
The Results (Study outcomes; page unavailable) report substantial LDL-C lowering overall. Table 1 records participants’ race, BMI and diabetes status, but the paper does not report efficacy across all ethnicities, BMI categories or glycemic states. The Methods (Study design and participants; page unavailable) place ORION-8 centres in Europe, North America and Africa, not China or Japan, so the claimed worldwide applicability is not established by this trial. (LLM, conf=0.89)
Experimental — accuracy not yet measuredThe analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants and showed inclisiran produces significant LDL-C reduction versus placebo treatment.
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [42]
The Introduction reports that a pooled analysis of three placebo-controlled trials found approximately 51% lower LDL-C with inclisiran than with placebo. But ORION-8 is an open-label extension of 3,274 patients; this paper does not report a quantitative synthesis of 11 RCTs involving more than 13,000 participants (Methods, Statistical analysis; Results, Demographic and clinical characteristics). (LLM, conf=0.88)
Experimental — accuracy not yet measuredThe studies presented demonstrated sustained maximum LDL-C reduction levels that persisted throughout six months following the last administered dose.
“The studies presented demonstrated sustained maximum LDL-C reduction levels that persisted throughout six months following the last administered dose [25, 42, 70].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [42]
The Results (Study outcomes; page not provided) report sustained LDL-C goal attainment at study visits, and the Discussion describes durable lowering with twice-yearly inclisiran. But the Methods (Study design and participants; page not provided) specify an end-of-study visit at Day 1080 or at least 90 days after the last dose. The paper does not establish that maximum LDL-C reduction persisted for six months following the final administered dose. (LLM, conf=0.87)
Experimental — accuracy not yet measured
ORION-8 demonstrated that only 2.4% of patients discontinued inclisiran due to treatment emergent adverse effects.
“ORION-8, a multicenter open-label extension of phase 2 (ORION-3) and phase 3 (ORION-9, -10, −11) trials involving 3,274 patients with a mean cumulative exposure of 3.7 years, demonstrated that only 2.4% of patients discontinued inclisiran due to treatment emergent adverse effects.118”
From Adherence to PCSK9 Inhibitors in Clinical Practice (2026) · cites this paper as [118]
Long-term results from ORION-8 indicated that twice-yearly dosing maintained LDL-C reductions for 6.8 years, allowing more than 78% of patients to meet guideline standards.
“Long-term results from ORION-8 indicated that the twice-yearly dosing-maintained LDL-C reductions for 6.8 years which allowed more than 78% of patients to meet guideline standards.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485 · see citing works
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
Self-citationTwo Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · see citing works
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works
Self-citationInclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · see citing works
Self-citationRay, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 8
- [1]Khvorova A. Oligonucleotide therapeutics -a new class of cholesterol-lowering drugs. N Engl J Med 2017; 376: 4– 7. 28052224
- [2]Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP, Investigators OPI. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol 2021; 77: 1182– 1193. 33663735
- [3]Lamb YN. Inclisiran: first approval. Drugs 2021; 81: 389– 395. 33620677 PMC7900795
- [7]Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol 2023; 82: 2251– 2261. 38057066
- [10]Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, Ferranti SD, Faiella-Tommasino J, Forman DE, et al 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082– e1143. 30586774 PMC7403606
- [11]Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020; 382: 1507– 1519. 32187462
- [14]Mu G, Xiang Q, Zhou S, Liu Z, Qi L, Jiang J, Gong Y, Xie Q, Wang Z, Zhang H, Huo Y, Cui Y. Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials. Adv Ther 2020; 37: 1496– 1521. 32108309
- [15]O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 2022; 146: 1109– 1119. 36031810
Cited by
Sorted by citations
Cesaro, A., Acerbo, V., Scialla, F., Zito, A., Porcelli, G., Panico, D., Argenziano, G., Iaria, D., Monaco, M. G., De Sio, V., et al. (2026) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.10.066 · Cited by 11 · see citing works
Jin, P., Ma, J., Wu, P., Yan, R., Bian, Y., Jia, S., Zheng, Q., & Ma, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117031 · Cited by 9 · see citing works
Adherence to PCSK9 Inhibitors in Clinical Practice
Blais, J. E., Zhong, W., Li, C. Y. V., Kongkaew, C., & Chan, A. H. Y. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102733 · Cited by 7 · see citing works
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5 · see citing works
“Inclisiran proved effective for all ethnicities and BMI categories as well as glycemic states and worldwide locations including South Africa, China and Japan thus proving its worldwide application [42].”
InfluentialEfficacy, benefit and safety of inclisiran
López-Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100730 · Cited by 4 · see citing works
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Singareddy, S., Dhakal, S., Limbaña, T. A., Murugan, V., Nazmin, F., Garcia, J., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.69918
- Authors
- Wright, R. S., Raal, F. J., Koenig, W., Landmesser, U., Leiter, L. A., Vikarunnessa, S., Lesogor, A., Maheux, P., Talloczy, Z., Zang, X., Schwartz, G. G., & Ray, K. K.
- Affiliations
- Mayo Clinic (US)
- University of the Witwatersrand (ZA)
- German Heart Centre, DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Technical University of Munich , Munich ,
- Deutsches Herzzentrum der Charité (DE)
- St. Michael's Hospital (CA)
- Novartis (United States) (US)
- Novartis (Switzerland) (CH)
- University of Colorado Anschutz (US)
- Imperial College London (GB)
- Corresponding author
- Wright, R Scott
- ORCID
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-05-16
- Volume
- 120
- Issue
- 12
- Pages
- 1400-1410
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC11481169
- OpenAlex
- W4397024469
- Cited by
- 102
- References
- 6
- Citations by year
- 2026: 44 · 2025: 46 · 2024: 12
- FWCI
- 42.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cardiovascular Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- inclisiran, LDL cholesterol lowering, long-term efficacy, long-term safety, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, PCSK9 inhibition, anti-drug antibodies, open-label extension, tolerability, injection-site adverse events, LDL cholesterol targets, lipid-lowering therapy, treatment-emergent adverse events
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Anticholesteremic Agents, Female, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Time Factors, Biomarkers, Down-Regulation, Treatment Outcome, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
